About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: LON
- Symbol: OXB
- Previous Close: $0.05
- 50 Day Moving Average: $4.11
- 200 Day Moving Average: $3.84
- 52-Week Range: £26,648,460 - GBX 2.98
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Market Cap: $107.13M
- Outstanding Shares: 2,664,846,000
Earnings History for Oxford BioMedica plc (LON:OXB)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Oxford BioMedica plc (LON:OXB)
Current Year EPS Consensus Estimate: $-0.53 EPS
Dividend History for Oxford BioMedica plc (LON:OXB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Oxford BioMedica plc (LON:OXB)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/24/2017||Lorenzo Tallarigo||Insider||Buy||67,165||GBX 4||£2,686.60|
|12/15/2016||Lorenzo Tallarigo||Insider||Buy||65,993||GBX 4||£2,639.72|
|11/25/2016||Lorenzo Tallarigo||Insider||Buy||75,417||GBX 4||£3,016.68|
|10/25/2016||Lorenzo Tallarigo||Insider||Buy||77,864||GBX 3||£2,335.92|
|9/26/2016||Lorenzo Tallarigo||Insider||Buy||79,988||GBX 3||£2,399.64|
|8/25/2016||Tallarigo ,Lorenzo||Insider||Buy||62,257||GBX 4||£2,490.28|
|7/25/2016||Tallarigo ,Lorenzo||Insider||Buy||63,351||GBX 4||£2,534.04|
|6/24/2016||Tallarigo ,Lorenzo||Insider||Buy||62,847||GBX 4||£2,513.88|
|5/13/2016||Diggle ,Martin||Insider||Buy||42,072||GBX 5||£2,103.60|
|5/12/2016||Diggle ,Martin||Insider||Buy||45,428||GBX 5||£2,271.40|
|5/5/2016||Diggle ,Martin||Insider||Buy||12,500||GBX 6||£750|
|5/4/2016||Diggle ,Martin||Insider||Buy||44,689||GBX 6||£2,681.34|
|5/3/2016||Diggle ,Martin||Insider||Buy||317,382||GBX 6||£19,042.92|
|4/22/2016||Tallarigo ,Lorenzo||Insider||Buy||41,083||GBX 6||£2,464.98|
|3/24/2016||Tallarigo ,Lorenzo||Insider||Buy||41,550||GBX 6||£2,493|
|2/26/2016||Diggle ,Martin||Insider||Buy||29,345||GBX 7||£2,054.15|
|2/25/2016||Tallarigo ,Lorenzo||Insider||Buy||36,370||GBX 7||£2,545.90|
|2/24/2016||Diggle ,Martin||Insider||Buy||46,693||GBX 6||£2,801.58|
|7/1/2015||Diggle ,Martin||Insider||Buy||284,439||GBX 0.09||£256|
|6/30/2015||Diggle ,Martin||Insider||Buy||775,000||GBX 0.09||£697.50|
|6/19/2015||Diggle ,Martin||Insider||Buy||225,000||GBX 0.08||£180|
|6/12/2015||Martin Diggle||Insider||Buy||283,978||GBX 9.01||£25,586.42|
|6/11/2015||Martin Diggle||Insider||Buy||416,022||GBX 9||£37,441.98|
|6/9/2015||Daniel Soland||Insider||Buy||500,000||GBX 9.45||£47,250|
|5/21/2015||Andrew Heath||Insider||Buy||100,000||GBX 10.60||£10,600|
|5/19/2015||Tim Watts||Insider||Buy||194,174||GBX 10.30||£19,999.92|
Latest Headlines for Oxford BioMedica plc (LON:OXB)
What is Oxford BioMedica plc's stock symbol?
Oxford BioMedica plc trades on the London Stock Exchange (LON) under the ticker symbol "OXB."
Where is Oxford BioMedica plc's stock going? Where will Oxford BioMedica plc's stock price be in 2017?
2 equities research analysts have issued twelve-month target prices for Oxford BioMedica plc's stock. Their predictions range from GBX 3.30 to GBX 8. On average, they anticipate Oxford BioMedica plc's share price to reach GBX 5.65 in the next year.
When will Oxford BioMedica plc announce their earnings?
Oxford BioMedica plc is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
How do I buy Oxford BioMedica plc stock?
Shares of Oxford BioMedica plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of Oxford BioMedica plc stock cost?
One share of Oxford BioMedica plc stock can currently be purchased for approximately GBX 4.02.